Specialty Pharmacy

Atezolizumab meets its primary endpoint of overall survival for patients with resected non-small cell lung cancer across most subgroups.

Study evaluates efficacy, immunogenicity, safety of the product to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Risankizumab-rzaa is the first and only specific IL-23 inhibitor approved to treat moderately to severely active Crohn disease in adults.

As more biosimilars and specialty generics enter the market next year, this could result in a shift in drug spending.

Pemigatinib is the first targeted therapy to gain FDA approval for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.

Risk factors associated with declining health-related quality of life for adult survivors of childhood cancer, such as physical inactivity and chronic health conditions, should be targets of surveillance and intervention.

Canakinumab did not meet the primary endpoint of disease-free survival in adult patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer.

Overall rates of early-stage cervical cancer in the United States have been falling, but cases with advanced disease are continuing to rise.

Ibrutinib (Imbruvica) is the first therapy to gain FDA approval for younger patients who had no prior treatment options for chronic graft-versus-host disease.

Zynteglo is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell transfusions.

Long-term follow up on the KEYNOTE-604 study suggests pembrolizumab plus etoposide/platinum is a superior first-line therapy for small cell lung cancer vs placebo.

In New York’s medical cannabis program, research showed that patients’ preference around potency differed among users, regardless of their health conditions.

Irinotecan liposomal injection (Onivyde) used as second-line therapy for patients with small cell lung cancer did not meet the primary end point of overall survival compared to topotecan.

Narcissistic leaders have a negative impact on the culture of their organization as their conduct and management style induces fear.

Oncology pharmacists must think critically about the digital experience they give patients.

Andrew Barnell, MBA, CEO and co-founder of Geneoscopy, discusses his meeting at the White House on President Biden’s Cancer Moonshot initiative.

Researchers suggest that immune checkpoint inhibitors significantly preserve the quality of life in patients with cancer.

For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.

Zynteglo was approved for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions after safety and efficacy were demonstrated in clinical trials.

FDA approved dexamethasone tablets USP 1.5mg, 4mg and 6mg, providing a new generic alternative to the steroid Decadron.

Gilead Sciences Inc submitted a supplemental Biologics License Application to the FDA for sacituzumab govitecan-hziy (Trodelvy) following promising trial results.

The Oncomine Dx Target Test is a next-generation sequencing–based companion diagnostic developed to analyze 23 genes associated with non–small cell lung cancer in patients who harbor an activating HER2 mutation.

A new study found that reduced tobacco use lowered deaths, person-years of lost life, and lost earnings across many states nationwide.

Zoledronic acid (Zometa) is indicated for the treatment of hypercalcemia that may occur with cancer.

Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.

Humate-P is indicated for the treatment of adult patients with classical hemophilia (hemophilia A) and von Willebrand disease (VWD).

Study finds link between higher insulin doses and the risk of developing cancer in patients with type 1 diabetes.

The FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu) to treat HER2 mutant non-small cell lung cancer was based on results from the DESTINY-Lung02 phase 2 trial.

New study shows that race does not influence outcomes from immunotherapy for aggressive triple-negative breast cancer.